PreprintArticleVersion 1Preserved in Portico This version is not peer-reviewed
Clinical Utility of Baseline Brain Natriuretic Peptide Levels on Health Status Outcomes after Catheter Ablation for Atrial Fibrillation in Individuals without Heart Failure
Kashimura, S.; Ikemura, N.; Kohsaka, S.; Katsumata, Y.; Kimura, T.; Shinmura, D.; Fukumoto, K.; Negishi, K.; Ueda, I.; Takatsuki, S.; Ieda, M. Clinical Utility of Baseline Brain Natriuretic Peptide Levels on Health Status Outcomes after Catheter Ablation for Atrial Fibrillation in Individuals without Heart Failure. J. Clin. Med.2024, 13, 407.
Kashimura, S.; Ikemura, N.; Kohsaka, S.; Katsumata, Y.; Kimura, T.; Shinmura, D.; Fukumoto, K.; Negishi, K.; Ueda, I.; Takatsuki, S.; Ieda, M. Clinical Utility of Baseline Brain Natriuretic Peptide Levels on Health Status Outcomes after Catheter Ablation for Atrial Fibrillation in Individuals without Heart Failure. J. Clin. Med. 2024, 13, 407.
Kashimura, S.; Ikemura, N.; Kohsaka, S.; Katsumata, Y.; Kimura, T.; Shinmura, D.; Fukumoto, K.; Negishi, K.; Ueda, I.; Takatsuki, S.; Ieda, M. Clinical Utility of Baseline Brain Natriuretic Peptide Levels on Health Status Outcomes after Catheter Ablation for Atrial Fibrillation in Individuals without Heart Failure. J. Clin. Med.2024, 13, 407.
Kashimura, S.; Ikemura, N.; Kohsaka, S.; Katsumata, Y.; Kimura, T.; Shinmura, D.; Fukumoto, K.; Negishi, K.; Ueda, I.; Takatsuki, S.; Ieda, M. Clinical Utility of Baseline Brain Natriuretic Peptide Levels on Health Status Outcomes after Catheter Ablation for Atrial Fibrillation in Individuals without Heart Failure. J. Clin. Med. 2024, 13, 407.
Abstract
Background: Catheter ablation (CA) benefits atrial fibrillation (AF) patients with heart failure (HF). Brain natriuretic peptide (BNP), a marker of left-ventricular pressure load, may serve as a potential surrogate for predicting quality of life (QOL) in broader range of patients. Methods: Within the multicenter KiCS-AF registry, 491 AF patients underwent CA without clinical HF (e.g. documented history of HF, left ventricular ejection fraction ≤40%, or BNP levels ≥100 pg/mL). Participants, aged 61±10 years, were categorized by baseline BNP quartiles. Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) questionnaire assessments were assessed at baseline and 1 year. Results: Lower baseline BNP correlated with reduced AFEQT scores. Post-CA, all groups showed significant AFEQT score improvements. Lower BNP group displayed notable enhancements (18.2±1.2, 15.0±1.1, 12.6±1.2, 13.6±1.2, p<0.005), especially in symptom and treatment concern areas. Even those with normal BNP levels (≤18.4 pg/ml) exhibited significant QOL improvements. Comparing PAF and non-PAF groups, the PAF group, especially with higher BNP levels, showed greater AFEQT score improvements. Conclusion: This study establishes BNP as a predictive marker for QOL enhancement in non-HF patients undergoing CA for AF. BNP levels represent AF stages, with individuals in earlier stages, especially within normal BNP levels, experiencing greater QOL improvement.
Keywords
atrial fibrillation; brain natriuretic peptide; catheter ablation; non–heart failure; quality of life
Subject
Medicine and Pharmacology, Cardiac and Cardiovascular Systems
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.